We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Biofluid Biomarkers of Mild Traumatic Brain Injury Whither Plasma Tau

Elaine R. Peskind, MD1,2; Brian Kraemer, PhD3,4; Jing Zhang, MD, PhD5
[+] Author Affiliations
1Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Seattle, Washington
2Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle
3Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington
4Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle
5Department of Pathology, University of Washington School of Medicine, Seattle
JAMA Neurol. 2015;72(10):1103-1105. doi:10.1001/jamaneurol.2015.1789.
Text Size: A A A
Published online


The search for plasma biomarkers of mild traumatic brain injury (mTBI) remains intense. The US Department of Defense and US Department of Veterans Affairs have invested more than $100 million toward this effort and the General Electric National Football League Challenge award made to Quanterix and Banyan Biomarkers is an indicator of the continued enthusiasm for this approach to biomarker discovery despite the current meager returns.

A handful of plasma biomarkers, including s100β, glial fibrillary acidic protein, neuron-specific enolase, myelin basic protein, and ubiquitin C-terminal hydrolase–L1, have consistently demonstrated to be elevated in acute and more severe head trauma13 and are informative with respect to prognosis.1 A single study in boxers following a bout showed elevated serum neuron-specific enolase that persisted for 2 months.4 However, no plasma or serum biomarkers have previously been identified that are persistently elevated in mTBI long after exposure. Whether mTBI, particularly, repetitive mTBI, which has been termed the signature injury of the wars in Iraq and Afghanistan, puts service members and veterans at long-term risk of tauopathy-related neurodegeneration and dementia is an urgent concern that has heightened the need for biofluid biomarkers of tauopathy. The difficulty in identifying blood biomarkers in mTBI is understandable given that most, if not all, central nervous system–derived markers are in extremely low concentration when measured in plasma or serum. Therefore, investigators and funding agencies have hoped that development of the ultrahigh-sensitivity Quanterix Simoa technology will be a game changer for identifying blood biomarkers of mTBI.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles